Drug
Riastap
Riastap: highest development phase Post-Market, developed by CSL. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- CSL
Trials
| Drug | Phase | Indication |
|---|---|---|
| RiaSTAP NCT01300286 | Post-Market | Coagulopathic Bleeding |
Latest
No recent events.
Follow Riastap on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.